NCT05292573View on ClinicalTrials.gov

Longitudinal Follow-up in Women With Endometrial Hyperplasia Without Atypia

PHASE3RecruitingINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

October 1, 2022

Study Completion Date

January 29, 2026

Conditions

Female

Interventions

DRUG

Metformin

During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.

Trial Locations (1)

333

RECRUITING

Chang Gung Memorial Hospital, Linkou Branch, Taoyuan District

All Listed Sponsors

lead

Chang Gung Memorial Hospital

OTHER

NCT05292573 - Longitudinal Follow-up in Women With Endometrial Hyperplasia Without Atypia | Biotech Hunter | Biotech Hunter